Related Experiment Video
Updated: May 28, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Effective pharmaceutical regulation needs alignment with doctors
Hans C Ebbers1, Toine Pieters, Hubert G Leufkens
1Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.
Drug Discovery Today
|October 18, 2011
Summary
Medical professionals distrust biosimilar drug approvals due to regulatory gaps. Enhanced collaboration between doctors and regulators is crucial for ensuring patient access to safe and effective innovative medicines.
Area of Science:
- Pharmacology and Drug Regulation
- Biotechnology and Biologics
Background:
- Medical community expresses concerns regarding the safety and efficacy of biosimilar drugs.
- This distrust suggests a potential erosion of confidence in established drug regulatory processes.
- Biosimilars, particularly biosimilar erythropoietins, are a recent focus of regulatory scrutiny.
Purpose of the Study:
- To analyze the development of the European regulatory framework for biosimilars.
- To examine the specific guidelines for approving biosimilar erythropoietins.
- To identify the role of the organized medical community in the regulatory guideline creation process.
Main Methods:
- Analysis of the European biosimilar regulatory framework.
- Focus on recently adopted guidelines for biosimilar erythropoietin approval.
- Observation of stakeholder involvement in the public guideline development process.
Main Results:
- The organized medical community was largely absent from the public process of creating and updating biosimilar guidelines.
- European regulatory framework for biosimilars, including erythropoietins, has been recently established.
- Concerns about biosimilar safety and efficacy reflect a distrust in the regulatory outcomes.
Conclusions:
- A closer collaboration between the organized medical community and drug regulators is necessary.
- This collaboration is essential for maintaining patient trust in the drug regulatory system.
- Ensuring continued patient access to innovative medicines requires improved regulatory engagement.
Related Concept Videos
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...